RxDoctor Payments Data

Stephanie Hyson Guevara, PA

Physician Assistant · Cartersville, GANPI 1174718647

Payments from drug & device makers

$984in general payments, 2019–2025

Across 49 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$143
  • Amgen$126
  • Novo Nordisk$124
  • AstraZeneca$103
  • AbbVie$87
  • Bayer$52
  • plus $348 from 14 others
$618in research payments, 2019–2025

Across 7 payments — averaging $88.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$618

What the payments were for

  • Food & beverage$984100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$984 in reported general payments places this provider in the 65th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$11,366
Medicare patients
67
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$17,259
FarxigaDapagliflozin Propanediol11$12,200
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,167
Tresiba Flextouch U-200Insulin Degludec11$6,809
Gabapentin36$909
Atorvastatin Calcium81$680
Albuterol Sulfate HfaAlbuterol Sulfate29$609
Levothyroxine Sodium42$354
Omeprazole27$320
Metoprolol Succinate29$306
Fluticasone Propionate23$263
Rosuvastatin Calcium15$248
Pantoprazole Sodium26$209
Amlodipine Besylate48$195
Lisinopril40$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$143$17,25911 claims
AstraZenecaFarxiga$103$12,20011 claims
GSKTrelegy Ellipta$34$8,16713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Cartersville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →